Arizona Oncology Revenue and Competitors

Catalina Foothills, AZ USA

Location

N/A

Total Funding

Estimated Revenue & Valuation

  • Arizona Oncology's estimated annual revenue is currently $83.2M per year.(i)
  • Arizona Oncology's estimated revenue per employee is $297,000

Employee Data

  • Arizona Oncology has 280 Employees.(i)
  • Arizona Oncology grew their employee count by -5% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$23.2M8616%N/AN/A
#2
$164M48633%N/AN/A
#3
$4.9M264%N/AN/A
#4
$0.9M740%N/AN/A
#5
$6.5M307%N/AN/A
#6
$271.4M718-8%N/AN/A
#7
$14.1M5814%N/AN/A
#8
$17.5M7222%N/AN/A
#9
$8M379%N/AN/A
#10
$33.2M1239%N/AN/A
Add Company

Arizona Oncology is one of the largest medical groups in Arizona. With more than 75 practicing physicians devoted exclusively to providing comprehensive, compassionate and high-quality cancer care, Arizona Oncology specializes in Medical, Gynecologic, and Radiation Oncology, Hematology, Stem Cell Transplant, Research, Genetic Risk Assessment and patient ancillary programs. The physicians and their staff treat patients in many communities throughout the state including: Chandler, Deer Valley, Estrella, Flagstaff, Glendale, Green Valley, Nogales, Phoenix, Prescott Valley, Safford, Scottsdale, Sedona, and Tucson.

keywords:N/A

N/A

Total Funding

280

Number of Employees

$83.2M

Revenue (est)

-5%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Arizona Oncology News

2022-04-20 - Changing the paradigm: How a veterinary oncologist informed ...

After earning an undergraduate degree in chemistry from University of Arizona and doctorates in veterinary medicine (1975) and radiation biology...

2022-03-30 - Maintenance Rucaparib Significantly Improves PFS in Phase ...

The drug's developer, Clovis Oncology, noted that these results will ... of Gynecologic Oncology at Arizona Oncology (US Oncology Network),...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$87.3M294-2%N/A
#2
$168.6M860N/AN/A
#3
$227.6M10841%N/A
#4
$269.6M11676%N/A
#5
$352.6M16790%N/A